Go Pro
→ He bet half his $9 billion on ONE stock (From Stansberry Research) (Ad)tc pixel Free GENF Stock Alerts

Genflow Biosciences (GENF) Competitors

Genflow Biosciences logo
GBX 1.92 0.00 (0.00%)
As of 07/20/2026 10:48 AM Eastern
Compare

GENF vs. COIL, POLB, SAR, COS, and C4XD

Should you buy Genflow Biosciences stock or one of its competitors? MarketBeat compares Genflow Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genflow Biosciences include Roquefort Therapeutics (COIL), Poolbeg Pharma (POLB), Sareum (SAR), Collagen Solutions plc (COS.L) (COS), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to Roquefort Therapeutics?

Roquefort Therapeutics (LON:COIL) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Genflow Biosciences Neutral

Genflow Biosciences has a net margin of -170.64% compared to Roquefort Therapeutics' net margin of -57,057.07%. Genflow Biosciences' return on equity of 332.06% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Genflow Biosciences -170.64%332.06%-58.66%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

Roquefort Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.297, meaning that its stock price is 130% more volatile than the broader market.

2.1% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 36.1% of Roquefort Therapeutics shares are owned by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Roquefort Therapeutics beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to Poolbeg Pharma?

Genflow Biosciences (LON:GENF) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by insiders. Comparatively, 7.5% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.95 indicating that Genflow Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Genflow Biosciences Neutral
Poolbeg Pharma Negative

Genflow Biosciences has a beta of 2.297, suggesting that its share price is 130% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.812, suggesting that its share price is 81% more volatile than the broader market.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

Poolbeg Pharma has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
Poolbeg Pharma N/A -55.47%-21.33%

Summary

Genflow Biosciences beats Poolbeg Pharma on 7 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to Sareum?

Sareum (LON:SAR) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Sareum is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SareumN/AN/A-£5.28M-£3.90N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

In the previous week, Sareum had 1 more articles in the media than Genflow Biosciences. MarketBeat recorded 1 mentions for Sareum and 0 mentions for Genflow Biosciences. Sareum's average media sentiment score of 0.34 beat Genflow Biosciences' score of 0.00 indicating that Sareum is being referred to more favorably in the media.

Company Overall Sentiment
Sareum Neutral
Genflow Biosciences Neutral

0.1% of Genflow Biosciences shares are held by institutional investors. 35.7% of Sareum shares are held by insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sareum has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Sareum's return on equity.

Company Net Margins Return on Equity Return on Assets
SareumN/A -284.01% -113.80%
Genflow Biosciences -170.64%332.06%-58.66%

Sareum has a beta of -1.08, suggesting that its share price is 208% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.297, suggesting that its share price is 130% more volatile than the broader market.

Summary

Genflow Biosciences beats Sareum on 7 of the 11 factors compared between the two stocks.

How does Genflow Biosciences compare to Collagen Solutions plc (COS.L)?

Collagen Solutions plc (COS.L) (LON:COS) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Collagen Solutions plc (COS.L) has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Collagen Solutions plc (COS.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Collagen Solutions plc (COS.L)N/A N/A N/A
Genflow Biosciences -170.64%332.06%-58.66%

Collagen Solutions plc (COS.L) has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than Collagen Solutions plc (COS.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collagen Solutions plc (COS.L)£4.01M0.00N/A-£0.80N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

In the previous week, Collagen Solutions plc (COS.L)'s average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Collagen Solutions plc (COS.L) Neutral
Genflow Biosciences Neutral

0.1% of Genflow Biosciences shares are owned by institutional investors. 25.8% of Genflow Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Genflow Biosciences beats Collagen Solutions plc (COS.L) on 5 of the 8 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

In the previous week, C4X Discovery's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
Genflow Biosciences Neutral

C4X Discovery has a net margin of 42.81% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat C4X Discovery's return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Genflow Biosciences -170.64%332.06%-58.66%

C4X Discovery has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.297, meaning that its share price is 130% more volatile than the broader market.

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 27.1% of C4X Discovery shares are held by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

C4X Discovery beats Genflow Biosciences on 8 of the 10 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GENF vs. The Competition

Export
MetricGenflow BiosciencesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£10.90M£444.73M£6.81B£2.79B
Dividend YieldN/A3.90%2.67%6.16%
P/E Ratio-5.803.4926.97368.25
Price / SalesN/A6,249.84507.3984,392.87
Price / Cash3.0013.1349.7127.89
Price / Book7.7687.6810.677.59
Net Income-£1.76M-£96.07M£3.60B£5.89B
7 Day Performance-3.27%-0.27%-0.99%0.16%
1 Month Performance-10.00%0.35%1.60%-0.87%
1 Year Performance150.00%57.77%24.14%62.65%

Genflow Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 1.93
flat		N/A+179.8%£10.90MN/AN/A5
COIL
Roquefort Therapeutics
N/AGBX 10
flat		N/A-41.2%£42.68MN/AN/A9
POLB
Poolbeg Pharma
N/AGBX 6.05
-13.6%		N/A+104.3%£42.66MN/AN/A12
SAR
Sareum
N/AGBX 22
-4.3%		N/A+46.0%£31.87MN/AN/A3,211
COS
Collagen Solutions plc (COS.L)
N/AN/AN/AN/A£30.99M£4.01MN/A3,350

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 7/22/2026 by MarketBeat.com Staff.
From Our Partners
The options guide that actually starts at the beginning
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...
Decentralized Masters | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
30-Year market veteran reveals America’s #1 Stock
Market veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...
Eagle Publishing | Sponsoredtc pixel
The SpaceX IPO Wasn't For You
Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...
Freedom Financial | Sponsoredtc pixel